KIT and acute myeloid leukemia: FLT3 mutations, particularly FLT3ITD are relatively rare in core-binding factor (CBF) AML, including those with RUNX1-RUNX1T1 or CBFB-MYH11 rearrangements and, not surprisingly, they are nearly mutually exclusive with activating mutations in RAS or KIT [16].